A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Eisai

Status: Active, not recruiting

Conditions: Lymphoma, Follicular

Treatments: Drug: Tazemetostat

Study type: Observational

Funder types: Industry

Identifiers

NCT05228158

E7438-M081-501

Details and patient eligibility

About

The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.

Enrollment: 145 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation
2. Participants treated with tazemetostat

Exclusion criteria

1. Participants with a history of hypersensitivity to any ingredient of Tazverik

Trial design

145 participants in 1 patient group

Tazemetostat

Description:

Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation will receive Tazemetostat 800 milligram (mg), tablet, orally, twice daily or as per physicians discretion in routine clinical practice. All the participants will be observed for up to Week 52 prospectively.

Treatment:

Drug: Tazemetostat